Drugs / SB 11285
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04096638 | Sep 2019 → Jul 2024 | head and neck squamous cell carcinoma, melanoma | invoX Pharma Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB 11285 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04096638 ↗ |
| Route | Intravenous | “for IV infusion” NCT04096638 ↗ |